Amgen, a major player in the pharmaceutical industry, has announced a significant investment in its Columbus, Ohio facility. During an interview on the Fox Business Network’s “The Claman Countdown,” CEO Robert Bradway revealed that the company will invest $1 billion to expand its operations there.
When asked about the impact of this investment on jobs, Bradway mentioned that the expansion will create several hundred permanent positions. This brings Amgen’s total investment in Columbus to $1.5 billion, and the facility will employ around 750 people in bio-manufacturing roles.
Bradway explained that this move is part of a larger trend of bringing manufacturing back to the United States, a shift influenced by policies from the Trump administration. He noted that from 2018 to 2024, Amgen invested $5 billion in U.S. manufacturing, resulting in an estimated $12 billion in additional economic activity.
The CEO also praised the tax reforms enacted in 2017, stating that they provided a solid foundation for Amgen’s growth in the U.S. He emphasized that the company’s manufacturing roots are in the United States, and these reforms have allowed them to continue expanding their domestic operations.
This investment underscores Amgen’s commitment to strengthening its manufacturing base in the U.S. and contributing to the local economy in Columbus.